(MedPage Today) — The phase III trial studying CRISPR gene editing therapy for transthyretin amyloidosis (ATTR) was paused for safety due to an alarming case of poor liver function in one patient, Intellia Therapeutics said.
A placebo-controlled…
Source link : https://www.medpagetoday.com/cardiology/generalcardiology/118177
Author :
Publish date : 2025-10-28 14:50:00
Copyright for syndicated content belongs to the linked Source.
